INTRODUCTION {#s1}
============

Medulloblastoma (MB) is a highly malignant neuroectodermal tumors, that belongs to high-grade glioma (HGG) and was categorized into WHO grade IV tumours of the Central Nervous System (CNS) \[[@R1]\]. MB commonly occurs among children, accounting for approximately 30% of pediatric CNS neoplasms; however, it is a rare disease among adults, with an annual incidence rate of 0.05 per 100,000 per year, which is fewer than 3% of all the primary neoplasms of the CNS \[[@R2], [@R3]\].

Controversy remains regarding the survival of MB between children and adults patients, some data suggests that adults fare better than children \[[@R4]\]. Emily K *et al.* reported that children and adults with MB do not differ with respect to overall survival, yet patients who are 3 years old or less fare significantly worse \[[@R5]\]. However, Rose Lai *et al.* suggested that the survival of children, especially older than 3 years of age, may be better than adults \[[@R6]\]. Furthermore, there has been no research that directly compare and evaluate the overall survival between children (4--19 years) with those of adults (≥ 20 years).

In children, the sample size was adequate in determining the clinical prognostic factors that guide the therapeutic strategies \[[@R7]\]; whereas in adults, the disease rarely occurred. The majority of reported survival rates and prognostic factors were based on single-institution comprising small series \[[@R8]--[@R11]\], or clinical studies that group together adult MB children MB, thus, the results may be inconclusive or may not permit a definite assessment of the prognostic role of clinical and pathologic factors to guide the therapy for adults. Previous studies suggested it is reasonable to consider grouping adults with children in clinical trials for MB \[[@R5]\]. However, there have been debates as to whether adults have a similar therapeutic response with that of children, such as radiotherapy or extent of surgery.

The Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute (NCI) could provide us with sufficient amount of patients who are representative of the US population, without selection biases. In this study, we aimed to determine whether adults and children with MB differ in survival, and to evaluate the prognostic factors or treatment efficacy in pediatric versus adult patients on a national level by using SEER database.

RESULTS {#s2}
=======

Patient characteristics {#s2_1}
-----------------------

A total of 965 MB worth of data on patients was analyzed in this study. Among these patients, 616 (63.8%) were children and 349 (36.2%) were adults. The median age was 8 years old for children and 31 years old for adults. The estimated 2- 5- and 10-year overall survival for children were 85.6%, 75.5%, and 67.9%, respectively, and the corresponding estimates for adults were 84.9%, 74.2%, and 67.3% (Figure [1](#F1){ref-type="fig"}). Epidemiological data showed that in the paediatric age group, MB occurred commonly during the first decade (38.5%) and in adults, the third decade (16.5%). The peak age of onset for MB patients was in those 9 years old and younger, after which the frequency appears to show an exponential decrease with age (Figure [2](#F2){ref-type="fig"}).

![Kaplan--Meier overall survival curves for children and adult patients with MB](oncotarget-09-30189-g001){#F1}

![Patients distribution by age at diagnosis in 965 patients with MB, diagnosed from 1992 to 2013](oncotarget-09-30189-g002){#F2}

The majority of patients are white (85.4%), and 61.5% of which are male. About 9.6% of histopathology was the desmoplastic nodular type, and 4.8% had the large cell /anaplastic variant. The gross total resection was determined for 59.0% patients, and over 80% of patients had radiotherapy. The majority of tumor (92.1%) located in infratentorial. About 11.7% of patients had spinal cord, cerebrospinal fluid (CSF), or extra neural metastases at the time of diagnosis. While comparing with adult MB patients, children MB patients were more likely to exhibit distal metastases (CSF, spinal cord or extra neural) (14.9% vs 6.0%), and slightly more often to be diagnosed in 2003--2013 (75.5% vs 69.3%). However, the characteristics and distribution of the two groups showed no significant difference concerning sex, race, histological type, tumor size, extent of surgery, radiotherapy, and site. A detailed listing of the patients' clinical characteristics was presented in Table [1](#T1){ref-type="table"}.

###### Demographic, tumor, and treatment characteristics

                                                            All patients   Children MB   Adult MB   *P* value                    
  --------------------------------------------------------- -------------- ------------- ---------- ----------- --------- ------ ---------
  **No. of patients**                                       965            100           616        63.8        349       36.2   \<0.001
  **Age**                                                                                                                        
  **Median**                                                                             8                      31               \<0.001
  **Interquartile range (years)**                           4--100                       4--19                  20--100          
  **Sex**                                                                                                                        
  **Male**                                                  593            61.5          381        61.9        212       60.7   0.735
  **Female**                                                372            38.5          235        38.1        137       39.3   
  **Race**                                                                                                                       
  **White**                                                 824            85.4          518        84.1        306       87.7   0.315
  **Non-white**                                             138            14.3          96         15.6        42        12.0   
  **Unknown**                                               3              0.3           2          0.3         1         0.3    
  **Marital status**                                                                                                             
  **Married**                                               159            16.5          2          0.3         157       45.0   \<0.001
  **Unmarried**                                             794            82.3          613        99.5        181       51.9   
  **Unknown**                                               12             1.2           1          0.2         11        3.2    
  **Histology**                                                                                                                  
  **Medulloblastoma**                                       822            85.2          524        85.1        298       85.4   0.208
  **Desmoplastic nodular medulloblastoma**                  93             9.6           54         8.8         39        11.2   
  **Medullomyoblastoma**                                    4              0.4           3          0.5         1         0.3    
  **Large cell /Anaplastic medulloblastoma**                46             4.8           35         5.7         11        3.2    
  **Tumor size (mm)**                                                                                                            
  **≤40**                                                   392            40.6          234        38          158       45.3   0.086
  **\>40**                                                  371            38.4          247        40.1        124       35.5   
  **Unknown**                                               202            20.9          135        21.9        67        19.2   
  **Treatment protocol**                                                                                                         
  **No treatment**                                          12             1.2           9          1.5         3         0.9    0.078
  **Surgery only**                                          121            12.5          72         11.7        49        14.0   
  **Radiation only**                                        7              0.7           4          0.6         3         0.9    
  **Surgery and radiation**                                 802            83.1          522        84.7        280       80.2   
  **Unknown**                                               23             2.4           9          1.5         14        4      
  **Extent of resection**                                                                                                        
  **NS**                                                    21             2.2           14         2.3         7         2.0    0.127
  **GTR**                                                   569            59.0          377        61.2        192       55     
  **STR**                                                   367            38.0          222        36.0        145       41.5   
  **Unknown**                                               8              0.8           3          0.5         5         1.4    
  **Radiation**                                                                                                                  
  **RT**                                                    817            84.7          528        85.7        289       82.8   0.268
  **No RT**                                                 133            13.8          81         13.1        52        14.9   
  **Unknown**                                               15             1.6           7          1.1         8         2.3    
  **Year of diagnosis**                                                                                                          
  **1992--2002**                                            258            26.7          151        24.5        107       30.7   0.038
  **2003--2013**                                            707            73.3          465        75.5        242       69.3   
  **Site**                                                                                                                       
  **Supratentorial**                                        44             4.6           31         5           13        3.7    0.140
  **Infratentorial**                                        889            92.1          560        90.9        329       94.3   
  **Others**                                                32             3.3           25         4.1         7         2      
  **Extent of disease at diagnoses**                                                                                             
  **Diseases confined to the brain**                        833            86.3          510        82.8        323       92.6   \<0.001
  **Distal metastases (CSF, spinal cord or extraneural)**   113            11.7          92         14.9        21        6.0    
  **Unknown**                                               19             2             14         2.3         5         1.4    
  **Vital status**                                                                                                               
  **Living**                                                725            75.1          468        76.0        257       73.6   0.420
  **Dead**                                                  240            24.9          148        24.0        92        26.4   

Abbreviations: GTR: gross total resection; STR: subtotal resection; NS: no surgery; RT: radiotherapy.

Univariate analysis {#s2_2}
-------------------

As shown in Table [2](#T2){ref-type="table"}, for all data gathered on patients, univariate survival analysis of clinical variables were evaluated with log-rank test. Histological type (Figure [3A](#F3){ref-type="fig"}), extent of resection (Figure [3B](#F3){ref-type="fig"}), radiotherapy (Figure [3C](#F3){ref-type="fig"}), extent of disease at diagnoses (Figure [3D](#F3){ref-type="fig"}) and year of diagnosis affected survival significantly (*P* \< 0.05), while age at diagnosis, sex, race, marital status, size, and primary site showed no significant association with survival (*P* \> 0.05).

###### Univariate analysis on the impact of patient, tumor and management factors on overall survival

                                                            Overall survival                          
  --------------------------------------------------------- ------------------ ------------ --------- ------------------------------------
  **Age**                                                                                             
  **4-19**                                                  0.90               0.69--1.16   0.411     **\>19**
  **Sex**                                                                                             
  **Female**                                                1.17               0.90--1.51   0.240     **Male**
  **Race**                                                                                            
  **White**                                                 1.09               0.75--1.59   0.659     **Non--white**
  **Marital status**                                                                                  
  **Married**                                               0.86               0.61--1.21   0.381     **Unmarried**
  **Histology**                                                                                       
  **Desmoplastic nodular MB**                               0.89               0.56--1.41   0.611     **MB**
  **Medullomyoblastoma**                                    1.95               0.49--7.87   0.347     
  **Large cell /Anaplastic MB**                             2.12               1.32--3.39   0.002     
  **Extent of resection**                                                                             
  **GTR**                                                   0.71               0.54--0.92   0.009     **STR**
  **NS**                                                    1.82               0.85--3.92   0.125     
  **Radiotherapy**                                                                                    
  **RT**                                                    0.41               0.30--0.56   \<0.001   **No RT**
  **Year of diagnosis**                                     0.95               0.93--0.98             
  **2003-2013**                                             0.68               0.52--0.88   0.004     **1992--2002**
  **Size (mm)**                                             1.00               0.98--1.01   0.523     
  **\>40**                                                  0.76               0.57--1.02   0.067     **≤40**
  **Site**                                                                                            
  **Infratentorial**                                        0.73               0.43--1.26   0.255     **Supratentorial**
  **Others**                                                1.80               0.87--3.73   0.114     
  **Extent of disease at diagnoses**                                                                  
  **Distal metastases (CSF, spinal cord or extraneural)**   1.79               1.30--2.48   \<0.001   **Diseases confined to the brain**

Abbreviations: GTR: gross total resection; STR: subtotal resection; NS: no surgery; RT: radiotherapy; HR: hazard ratio; CI: confidence interval.

![Kaplan--Meier overall survival curves stratified by (**A**) histological type, (**B**) extent of resection, (**C**) radiotherapy, (**D**) extent of disease at diagnoses for patients with MB.](oncotarget-09-30189-g003){#F3}

Multivariate analysis {#s2_3}
---------------------

Multivariate analysis performed with the Cox proportional hazards regression model indicated that when analyzing for all patients, radiotherapy, histology, and extent of disease at diagnosis were the independent prognostic factors of survival (*P* \< 0.05). Radiation utilization was significantly associated with reduced hazard of mortality (HR 0.41, 95% CI 0.28--0.60); whereas LC/A subtype (HR 2.31, 95% CI 1.34--3.97) and distal metastases (CSF, spinal cord or extraneural) (HR 1.66, 95% CI 1.12--2.48) were of poor prognosis. When the analysis was restricted to children, we found it interesting that similar results were observed except for the LC/A subtype (HR 1.95, 95% CI 1.00--3.83). However, in the adult group, different results were noted when comparing with children. LC/A subtype consistently associated with poor survival (HR 4.33, 95% CI 1.69--11.11). GTR was associated with good prognosis (HR 0.56, 95% CI 0.35 --0.90), while CSF, spinal cord, or extraneural metastases failed to show any statistical significance (HR 1.33, 95% CI 0.59--3.01). Radiotherapy was the only identical prognostic factor observed between children (HR 0.36, 95% CI 0.22--0.60) and adults (HR 0.47, 95% CI 0.26--0.84), which was associated with better survival.

DISCUSSION {#s3}
==========

This study has compared the survival, clinical characteristics, and prognostic factors of children and adults with MB in a large series of patients contemporarily, showing that children and adults may have very similar outcomes, while the prognostic factors in adult MB are not comparable to those in children. Radiotherapy was the only identical prognostic factor observed in the two groups. In addition, distal metastases was a significant negative prognostic factor restricted to children, while GTR was a favorable prognostic factor, and LC/A histologic subtype was associated with poor survival for adults.

The 5- year overall survival rate for children is 75.5%. This is higher than the reported 50% by Karoly *et al.* in a series of 80 cases \[[@R12]\], but it is comparable to those who reported approximately 70% in other series of children \[[@R13]\]. The estimated 5- and 10-year survival rates for adults are 74.2% and 67.3% respectively, which are higher than the reported 72% and 55% in the French multi-center cohort of 253 patients \[[@R14]\]. Nevertheless, no significant difference of survival was observed between the two groups in our cohort, which was consistent with previously reported data, indicating that the survival was not affected by age at tumour onset \[[@R15]\] (Figure [1](#F1){ref-type="fig"}). However, our data did not support the extrapolation of Rose Lai' s study that the relative survival of children with MB, especially in those older than 3 years of age, may be better than that in adults \[[@R6]\]. MB can affect individuals of all ages, which is common in children but is rare in adults \[[@R16]\]. Furthermore, our findings suggested that in the paediatric age group, MB occurred commonly in the first decade and in adults, the third decade, which was in accordance with the previous studies \[[@R3], [@R17]--[@R19]\]. In addition, the distribution of cases according to age at diagnosis showed an exponential decreasing trend (Figure [2](#F2){ref-type="fig"}). Notably, the CSF, spinal cord, or extraneural metastases, a worse clinical feature, was observed to be more frequent in children patients rather than in adults (Table [1](#T1){ref-type="table"}), which may suggest a unique clinicobiological characteristic underlying children, in whom this tumor commonly occurs. In addition, there were more pediatric MB after 2003 (Table [1](#T1){ref-type="table"}), which may be largely due to diagnostic improvements in brain-tumor imaging \[[@R3]\].

Our study confirmed that LC/A subtype and distal CSF, spinal cord, or extraneural metastases were the main adverse prognostic factors when analyzing all MB patients, while radiotherapy was correlated with a better prognosis (Table [3](#T3){ref-type="table"}). When the analysis was restricted to children, LC/A subtype no longer had prognostic value, which was inconsistent with the previous studies that suggested children LC/A subtype was associated with an impaired prognosis of patients and inferior survival rates \[[@R20]--[@R22]\]. Given the low incidence of LC/A medulloblastoma, numbers of patients with this MB variant described in the literature were only limited. In addition, some investigators also suggested that patients with LC/A subtype can have favorable survival rates if clinical risk factors as metastases and young age are absent \[[@R23]\]. Thus this discrepancy might mainly because that the population in our study is relatively different compared to the previous studies. Likewise, when the analysis was restricted to adult, the LC/A subtype was shown to carry the worst prognosis among all histologic subtypes, while distal metastases was of no statistical significance in the multivariate model. The discrepancy in outcomes with distant metastases which might be associated with the different tumourigenic mechanisms involved in the development of MB \[[@R24]\], patients with MB in adults and children are histologically and genetically different diseases, with more mutations being observed in children \[[@R25], [@R26]\]. Furthermore, adult tumors were biologically less aggressive, having lower growth rate parameters as compared to childhood tumors \[[@R27]\]. These results again agreed with previous research \[[@R6]\]. Another discrepancy with children is that GTR was associated with a better outcome in adult group (Table [3](#T3){ref-type="table"}). Which may be attributable to that childhood tumors were more commonly of midline cerebellar vermis, \[[@R28], [@R29]\], many MB have an attachment to the floor of the fourth ventricle or brainstem, aggressive initial surgical resection can greatly increase surgical complications \[[@R30]--[@R32]\]. Thompson *et al.* have also identified that there is no overall survival benefit for GTR over STR \[[@R32]\]. While the lateral location occurred more frequently in adults \[[@R28]\], which enabled total resection of tumors without affecting the function of critical structures, resulting in improved long-term survival \[[@R11], [@R33]\]. In addition, adult MB patients are more amenable to complete surgical clearance than children. Rose Lai and Chan's group also reported similar results \[[@R6], [@R8]\]. However, the complete resection in 1 study only resulted in severely reduced postoperative performance status \[[@R7]\].

###### Multivariate analysis of patient and treatment factors in MB patients diagnosed from 1992 to 2013

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                             All patients                   Children                           Adult                            Comparison group
  ----------------------------------------------------- -------------------- --------- ------------------------ --------- ------------------------ ------- --------------------------------
  Histology                                                                                                                                                

  Desmoplastic nodular MB                               0.87 (0.49--1.54)    0.628     0.31 (0.10--1.00)        0.050     1.82 (0.91--3.63)        0.089   MB

  Medullomyoblastoma                                    2.54 (0.61--10.48)   0.198     2.81 (0.66--11.98)       0.163     0.00 (0.00--4.12E+194)   0.972   

  Large cell /Anaplastic MB                             2.31 (1.34--3.97)    0.003     1.95 (1.00--3.83)        0.051     4.33 (1.69--11.11)       0.002   

  Extent of resection                                                                                                                                      

  GTR                                                   0.76 (0.56--1.03)    0.078     0.96 (0.64--1.43)        0.822     0.56 (0.35--0.90)        0.016   STR

  NS                                                    0.37 (0.05--2.68)    0.325     0.00 (0.00--2.18E+195)   0.962     0.71 (0.10--5.34)        0.742   

  Radiotherapy                                                                                                                                             

  RT                                                    0.41 (0.28--0.60)    \<0.001   0.36 (0.22--0.60)        \<0.001   0.47 (0.26--0.84)        0.011   No RT

  Size (mm)                                                                                                                                                

  \>40                                                  0.80 (0.59--1.09)    0.150     0.77 (0.52--1.15)        0.200     0.88 (0.54--1.43)        0.611   ≤40

  Extent of disease at diagnoses                                                                                                                           

  Distal metastases (CSF, spinal cord or extraneural)   1.66 (1.12--2.48)    0.012     1.86 (1.17--2.97)        0.009     1.33 (0.59--3.01)        0.490   Diseases confined to the brain

  Year of diagnosis\                                    0.74 (0.53--1.03)    0.072     0.75 (0.48--1.17)        0.206     0.68 (0.41--1.12)        0.128   1992--2002
  2003--2013                                                                                                                                               
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: GTR: gross total resection; STR: subtotal resection; NS: no surgery; RT: radiotherapy; HR: hazard ratio; CI: confidence interval.

In a previous multicenter, retrospective study on MB, certain prognostic factors in adults have been demonstrated to be similar to those observed in children such as brainstem, floor of fourth ventricle involvement, and dose to the posterior cerebral fossa \[[@R14]\]. Notably, in our study, craniospinal irradiation, a main treatment modality for MB, was demonstrated to be the only identical prognosis factor of the two groups, which was correlated with a longer survival. Nevertheless, these results cannot be considered conclusive, since the efficacy and patients' survival were determined and influenced by the quality of the regimens and the dose administered to different targets. For example, radiation dose to the posterior fossa less than 50 Gy has been reported to be a poor prognostic factor \[[@R14]\], while a high radiation dose to the spinal cord was correlated with a better outcome \[[@R7]\]. In addition, cumulated doses were heterogeneous. Unfortunately, the SEER data did not provide information on details of radiation dosage.

Despite the fact that the survival of this disease would be improved due to enhanced imaging technologies, improved surgical planning, and radiation techniques, it is worth noting in this cohort year of diagnosis was not found to be a prognostic factor. In addition, in this study, tumor size was unable to be established for prognostic value, which again appeared to be consistent with the findings of another series \[[@R6]\].

Some major limitations in the current study due to intrinsic limitations in the SEER database made the interpretation of the results difficult. First, no central review of the histologic specimens could be performed. Second, inadequate data, such as total dose, fraction size, radiation ports, and radiation volume were provided in the SEER registry. Third, even though the four core subtypes of MB, including WNT, SHH, Group 3, and Group 4, have been demonstrated to be correlated with patients' survival and response to treatment \[[@R34]\], information on genetic profiles were unavailable. Forth, information regarding various clinical variables, such as patient performance status and duration of symptoms were unavailable. Last, lack of information on chemotherapy regimens, which might potentially confound our results.

In conclusion, this preliminary study based on SEER database helped to determine some basic survival parameters and prognostic factors. Despite the fact that children patients tend to exist more distal metastases, and did not show any survival benefit when treated with GTR as opposed to the adults, children and adult patients with MB did not differ with respect to the overall survival. Radiotherapy was demonstrated to be the only identical prognostic factor, that could reduce the fatal risk of MB, for both children and adult patients.

MATERIALS AND METHODS {#s4}
=====================

Patient population {#s4_1}
------------------

We performed a retrospective analysis using SEER Program ([www.seer.cancer.gov](http://www.seer.cancer.gov)) and SEER\*Stat Database: Incidence-SEER 18 Registries Limited Use, November 2015 Submission (1973--2013), National Cancer Institute, Division of Cancer Control and Population Sciences (DCCPS), Surveillance Research Program, Cancer Statistics Branch, released April 2016, based on the November 2015 submission \[[@R35]\]. The SEER database provides information about the patients' demographic characteristics, type of malignancy, treatment protocols, and clinical information at the time of diagnosis. Patients were followed-up annually for survival status. We extracted the data of patients with MB cases from SEER 18 registries using the following parameters: age \> 3 years old, International Classification of Disease in Oncology 3rd edition (ICD-O3) code 9470, 9471, 9472, and 9474, primary site in the cerebellum and other clinically relevant. Patients without histological confirmation, patients with death certificate only, and patients with multiple primary tumors without active follow-up or explicit survival results were excluded from the survival study to improve the accuracy of survival analyses. The study period was 1992--2013. Information was obtained about their demographic characteristics, year of diagnosis, and duration of survival. However, the data on patient symptoms, performance status, and treatments such as adjuvant chemotherapy are not available in the database. Also this research did not involve interaction with human subjects or the use of any personal identifying information. Hence, it was exempted from the institutional review board approval. Informed consent was not applicable to this study.

Patient population and variable collection {#s4_2}
------------------------------------------

There were 965 patients studied who were diagnosed with MB between 1992 and 2013. Among the demographic variables, according to the age at diagnosis, data were compared with children (between 4 and 19 years of age) and adults (≥20 years). Demographic and clinical variables included sex (male, female), race/ethnicity (white, non-white), marital status at diagnosis (married, unmarried, unknown), histologic subtype (medulloblastoma, desmoplastic nodular medulloblastoma, medullomyoblastoma, and large cell /anaplastic (LC/A) medulloblastoma), tumor size (by category: ≤4 cm, \>4 cm), year of diagnosis (1992--2002, 2003--2013), extent of surgery (gross total resection, subtotal resection, or no surgery), and radiotherapy status (radiotherapy, no radiotherapy), primary tumor sites (supratentorial, infratentorial, others), extent of disease at diagnoses (diseases confined to the brain, distal metastases to CSF, spinal cord or extraneural), when applicable, were also recorded. Data regarding the use of adjuvant chemotherapy was not available in the SEER database.

Statistical analysis {#s4_3}
--------------------

Statistical analysis was performed using SPSS statistical software version 19.0 (SPSS Inc., IBM Corporation, Chicago, IL, USA). Significant differences in patient demographics and tumor characteristics between the two groups were detected using the Pearson Chi-square test and the Wilcoxon rank sum test. Overall mortality was chosen as an endpoint. Survival was calculated using the Kaplan-Meier method and the log-rank test was used to compare survival curves. Univariate and multivariate models were established to evaluate correlations between various covariates and survival. Those variables that achieved a *P*-values \< 0.1 were included in a multivariable Cox proportional hazard model. We reported our findings using hazard ratios (HRs), 95% confidence intervals (CIs), and *P* values. Two-sided *P*-values \< 0.05 were considered statistically significant.
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